Cooperative Agreement HT94252420009
Award Date
9/15/24
Completion Date
9/14/28
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
12.420
Assistance Type
Cooperative Agreement
Place of Performance
Durham, NC 27705, USA
Similar Awards
The Department of the Army Medical Command awarded Duke University a $1,932,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the period of September 1, 2022 through August 31, 2025. The grant funds research to define cellular and genetic factors for renal cell carcinoma subtypes. Through this award, Duke University researchers will investigate medical solutions for kidney cancer on the cellular and genetic levels to advance understanding,...
This federal Project Grant award from the Department of the Army Medical Command, under the Military Medical Research and Development program (CFDA 12.420), provides $241,500.00 to Duke University to conduct research on "UNDERSTANDING THE MOLECULAR COMMUNICATION BETWEEN PROSTATE CANCER CELL TYPES". The award period runs from Sep 1, 2025 to Aug 31, 2027. The research aims to advance scientific understanding and potential treatments for prostate cancer, a critical priority for the...
This $1,090,116 Cooperative Agreement award from the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program supports a clinical trial site application for the Kidney Cancer Research Consortium at the University of Texas Southwestern Medical Center (UT Southwestern). The award provides funding for UT Southwestern to exercise an option year and add additional funding for the consortium's kidney cancer clinical trials. The project aims to...
This federal Cooperative Agreement award of $1,300,003.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports a clinical trial site application for kidney cancer research at the University of Pennsylvania. The award exercises an option year and provides additional funding to continue the University of Pennsylvania's participation in the Kidney Cancer Research Consortium. The research aims to advance scientific understanding...
The Department of the Army Medical Command awarded Duke University a $2,139,404 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support research on exploiting a new targetable node in the androgen receptor (AR) signaling pathway in prostate cancer. The three-year award runs from January 7, 2022 to June 30, 2025. Duke University will conduct research to transform healthcare for service members and the public through innovative and impactful medical...
The Department of the Army Medical Command awarded Vanderbilt University Medical Center a $1.4 million cooperative agreement from September 15, 2021 to September 14, 2024 under the Military Medical Research and Development program (CFDA 12.420). The award will support Vanderbilt's Kidney Cancer Clinical Trials Consortium to conduct clinical trials investigating medical solutions for kidney cancer through the Military Medical Research and Development program's goals of transforming military and...
This Cooperative Agreement award of $1,248,000.00 from the Defense Health Agency supports Phase 1/2 clinical trials assessment of kidney cancer therapeutics at the University of Michigan under the Military Medical Research and Development (CFDA 12.420) program. The project, titled "University of Michigan Phase 1/2 Clinical Trials Assessment in Kidney Cancer Therapeutics (U-MPAKT)," will focus on advancing innovative medical solutions for the treatment of kidney cancer, which is a...
The Department of the Army Medical Command awarded Duke University a $784,385 Project Grant on September 30, 2022 to complete work by September 29, 2025. The grant supports the "Modulation of Tumor Microenvironment to Hinder Cancer Progression and Therapeutic Resistance" project under the Military Medical Research and Development program (CFDA 12.420). This program aims to transform military and public health through innovative biomedical research solutions. Duke University will...
The Department of the Army Medical Command awarded Duke University a $482,890 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from April 1, 2022 to March 31, 2024 to target the oncogenomic function of the E2F8 transcription factor in lethal prostate cancer. Through this funding, Duke University researchers will investigate medical solutions for prostate cancer at the genomic level, with the aim of transforming healthcare for...
This Cooperative Agreement award of $1,028,005.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award supports the DF/HCC Clinical Trials Site Application for the Kidney Cancer Research Consortium, including exercising an option year and adding additional funding. The primary awardee is Beth Israel Deaconess Medical Center, Inc. (BIDMC), a prominent non-profit academic medical center in Boston, MA. Through...